ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO700

Examining the Magnitude of Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Weinhandl, Eric D., Chronic Disease Research Group, Minneapolis, Minnesota, United States
  • Hwang, Yunji, Amgen Inc, Thousand Oaks, California, United States
  • Gilbertson, David T., Chronic Disease Research Group, Minneapolis, Minnesota, United States
  • Petersen, Jeffrey, Amgen Inc, Thousand Oaks, California, United States
Background

Anemia is common in patients undergoing maintenance hemodialysis (HD) and is treated with erythropoiesis-stimulating agents (ESAs) and intravenous iron. ESA hyporesponsiveness is an oft-cited unmet medical need, but the scope of the problem is obscured by complex statistical quantities, including the erythropoietin resistance index (ERI). We analyzed a contemporary, nationally representative cohort to describe anemia-related parameters of HD patients with high ERI and/or chronically low hemoglobin (Hb).

Methods

We analyzed CROWNWeb records of HD patients in 2016-2019. The study cohort included 6-month patient-intervals characterized by treatment with either epoetin alfa (EPO) or darbepoetin alfa (DPO), monthly measurements of Hb, and at least one measurement of transferrin saturation (TSAT). We stratified patient-intervals by the cross-classification of normal vs high ERl (definition: ≥20 EPO-equivalent IU/wk/kg/g/dL, where 1 mcg DPO = 250 IU EPO) and transiently vs chronically low Hb (definition: Hb <10 g/dL in every month of the interval). In each stratum, we estimated median values of weekly ESA dose, Hb, ERI, and TSAT.

Results

We identified 7,824,640 patient-intervals. Prevalence of high ERI was 17.2% in single patient-months and 15.6% during 6-month patient-intervals. In both cases, ERI was strongly correlated with weekly ESA dose (R2 = 0.87). In contrast, prevalence of Hb <10 g/dL was 23.0% in single patient-months, whereas prevalence of chronically low Hb was 2.5% during 6-month patient-intervals (table). Among 15.6% of patients with high ERI, 13.8% experienced only transiently low Hb, with median Hb of 10.1 g/dL and median TSAT of 25.0%. Among 2.5% of patients with chronically low Hb, 1.8% experienced high ERI, with median TSAT of 23.0%.

Conclusion

Prevalence of high ERI in HD patients exceeds 15%, mostly due to the scale of ESA dosing, but this overstates the prevalence of chronic anemia hyporesponsive to treatment. Lower TSAT is common in patients with high ERI and/or chronically low Hb, suggesting potential iron deficiency.

 Normal ERIHigh ERI
 Transiently
low Hb
Chronically
low Hb
Transiently
low Hb
Chronically
low Hb
Patient-intervals (row %)83.7%0.7%13.8%1.8%
ESA dose (EPO-equivalent IU/wk)5136862419,80925,106
Hb (g/dL)10.78.910.18.5
ERI (IU/wk/kg/g/dL)3.93.525.033.3
TSAT (%)30.026.025.023.0

Funding

  • Commercial Support